According to the SEC’s order, BD determined in 2016 that software changes made to the Alaris pump required regulatory clearance from the Food and Drug Administration (FDA). However, BD did not ...

BD decided to continue to selling the Alaris pumps with the improvement without the clearance for it. The SEC said that by January 2019, the company found more than 25 flaws with the software that ...

Michael David Garrison, Executive Vice President and President of Medical (TASE:PMCN) at Becton Dickinson & Co. (NYSE:BDX), recently sold 597 shares of the company’s common stock. The shares were sold ...